ASX Announcement Retirement of Non-Executive Director SYDNEY Australia, 4 November 2026: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company or Recce), a leading developer of a new class of Synthetic Anti-infectives, advises that Mr Alistair McKeough, Independent Non-Executive Director, has...
Retirement of Mr Alistair McKeough as Non-Executive Director
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Recce Pharmaceuticals Ltd. announces the retirement of Mr. Alistair McKeough as Non-Executive Director, effective after the upcoming Annual General Meeting. Mr. McKeough will not seek re-election, and the related resolution has been withdrawn from the AGM agenda. Dr. Alan Dunton will take over as Chair of the Audit and Risk Committee following the AGM. The announcement highlights Mr. McKeough's contributions and the company's focus on developing anti-infectives.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Recce Pharmaceuticals Ltd. on 6ix
In the deck
Earlier from Recce Pharmaceuticals
- Options Prospectus
- Cleansing Notice
- Application for quotation of securities - RCE
- Quarterly Activities/Appendix 4C Cash Flow Report
- License and Commercialisation Agreement in AUS/NZ for R327G
Later from Recce Pharmaceuticals
- AGM Presentation
- Results of Meeting
- Final Director's Interest Notice - Mr McKeough
- Notification regarding unquoted securities - RCE
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals